A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

[11C]savolitinib

Radiopharmaceutical; IMP; Sterile solution for IV injection, not more than 10 μg, single administration

DRUG

Savolitinib

IMP; 300 mg tablet, oral single administration

Trial Locations (1)

Research Site, Solna